Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
Primary Purpose
Atopic Asthma
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Bone Marrow Aspiration
Tonsil Biopsy
Sponsored by

About this trial
This is an interventional basic science trial for Atopic Asthma focused on measuring Allergen Challenge, B cell activation, M1 prime related biomarkers
Eligibility Criteria
Inclusion Criteria:
- Male and female volunteers 18 through 65 years of age.
- Females must not be actively seeking pregnancy, must be using adequate and effective contraception
- General good health
- Mild to moderate, stable, allergic asthma
- History of episodic wheeze and shortness of breath; FEV1 at baseline at least 70% of the predicted value
- Able to understand and give written informed consent and has signed a written informed consent form approved by the investigator's REB
- Positive methacholine challenge
- Positive skin-prick test to common aeroallergens (including cat, dust mite, grass, pollen)
- Positive allergen-induced airway bronchoconstriction (a fall in FEV1 of at least 20% from baseline)
Exclusion Criteria:
- A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry
- History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness
- History or symptoms of clinically significant autoimmune disease
- History of clinically significant hematologic abnormality, including coagulopathy
- Be pregnant or lactating
- Use of corticosteroids, immunosuppressives, anticoagulants (warfarin or heparin) within 28 days prior to randomization into the study
- Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hours of dosing or aspirin with 7 days of dosing
- Have chronic use of any other medication for treatment of allergic lung disease other than short- and intermediate-acting ß2-agonists or ipratropium bromide
- Use of caffeine-containing products or medications for 12 hours or alcohol or over the counter drugs including aspirin, cold and allergy medications for 48 hours or inhaled bronchodilators for 8 hours prior to methacholine and allergen challenges
- Use of tobacco products of any kind currently or within the previous 12 months, or smoking history > 10 pack years.
- Lung disease other than mild to moderate allergic asthma
- Unwillingness or inability to comply with the study protocol for any other reason.
Sites / Locations
- Cardio- Respiratory Research Laboratory, Hamilton Health Sciences
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Allergen Challenge
Arm Description
Outcomes
Primary Outcome Measures
To characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers.
Secondary Outcome Measures
Full Information
NCT ID
NCT01420003
First Posted
August 17, 2011
Last Updated
March 19, 2015
Sponsor
Hamilton Health Sciences Corporation
Collaborators
Genentech, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01420003
Brief Title
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
Official Title
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hamilton Health Sciences Corporation
Collaborators
Genentech, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers.
Detailed Description
M1 prime is a segment of IgE found only in the membrane form of IgE and not on soluble IgE found in serum. Membrane IgE (and M1prime) is expressed on IgE-switched B cells, IgE-memory B cels, and IgE-plasmablasts. Depletion of IgE-switched B cells and plasmablasts will reduce IgE-producing cells and serum IgE, and may be a target for treatment of allergic asthma. A humanized antibody targeting M1 prime is being developed by Genentech, Inc., as a potential therapeutic for asthma.
Currently, the efficacy of MEMP1972A is being assessed in an allergen challenge study in mild asthmatics (MOP4843g). Extensive biomarker samples have been incorporated in that study to characterize the mechanism of action (MOA) as well as the kinetics of the MOA of MEMP1972A, which are poorly understood at this time. Furthermore, samples for the B cell enriched peripheral blood flow cytometry and bone marrow aspirates to evaluate the kinetics and MOA of MEMP1972a are collected only 24 hr after allergen challenge due to visit and sample volume limitations. It is known that maximal B cell responses are expected ~7 days after allergen stimulation. Therefore, the purpose of this research study will be to characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Asthma
Keywords
Allergen Challenge, B cell activation, M1 prime related biomarkers
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Allergen Challenge
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Bone Marrow Aspiration
Intervention Description
3 per study
Intervention Type
Procedure
Intervention Name(s)
Tonsil Biopsy
Intervention Description
Optional upon completion of study
Primary Outcome Measure Information:
Title
To characterize the time course of B cell activation after allergen challenge, and more specifically measure the M1 prime related biomarkers.
Time Frame
Within 7 days of allergen challenge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female volunteers 18 through 65 years of age.
Females must not be actively seeking pregnancy, must be using adequate and effective contraception
General good health
Mild to moderate, stable, allergic asthma
History of episodic wheeze and shortness of breath; FEV1 at baseline at least 70% of the predicted value
Able to understand and give written informed consent and has signed a written informed consent form approved by the investigator's REB
Positive methacholine challenge
Positive skin-prick test to common aeroallergens (including cat, dust mite, grass, pollen)
Positive allergen-induced airway bronchoconstriction (a fall in FEV1 of at least 20% from baseline)
Exclusion Criteria:
A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry
History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness
History or symptoms of clinically significant autoimmune disease
History of clinically significant hematologic abnormality, including coagulopathy
Be pregnant or lactating
Use of corticosteroids, immunosuppressives, anticoagulants (warfarin or heparin) within 28 days prior to randomization into the study
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hours of dosing or aspirin with 7 days of dosing
Have chronic use of any other medication for treatment of allergic lung disease other than short- and intermediate-acting ß2-agonists or ipratropium bromide
Use of caffeine-containing products or medications for 12 hours or alcohol or over the counter drugs including aspirin, cold and allergy medications for 48 hours or inhaled bronchodilators for 8 hours prior to methacholine and allergen challenges
Use of tobacco products of any kind currently or within the previous 12 months, or smoking history > 10 pack years.
Lung disease other than mild to moderate allergic asthma
Unwillingness or inability to comply with the study protocol for any other reason.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gail M Gauvreau, PhD
Organizational Affiliation
McMaster Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardio- Respiratory Research Laboratory, Hamilton Health Sciences
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3Z5
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
18166595
Citation
Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008 Jan;31(1):143-78. doi: 10.1183/09031936.00138707. Erratum In: Eur Respir J. 2018 Jan 31;51(2):
Results Reference
background
PubMed Identifier
17983880
Citation
National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. doi: 10.1016/j.jaci.2007.09.043. Erratum In: J Allergy Clin Immunol. 2008 Jun;121(6):1330.
Results Reference
background
PubMed Identifier
10779282
Citation
Sears MR, Burrows B, Flannery EM, Herbison GP, Holdaway MD. Atopy in childhood. I. Gender and allergen related risks for development of hay fever and asthma. Clin Exp Allergy. 1993 Nov;23(11):941-8. doi: 10.1111/j.1365-2222.1993.tb00279.x.
Results Reference
background
PubMed Identifier
6601124
Citation
Boulet LP, Cartier A, Thomson NC, Roberts RS, Dolovich J, Hargreave FE. Asthma and increases in nonallergic bronchial responsiveness from seasonal pollen exposure. J Allergy Clin Immunol. 1983 Apr;71(4):399-406. doi: 10.1016/0091-6749(83)90069-6.
Results Reference
background
PubMed Identifier
2710172
Citation
Anto JM, Sunyer J, Rodriguez-Roisin R, Suarez-Cervera M, Vazquez L. Community outbreaks of asthma associated with inhalation of soybean dust. Toxicoepidemiological Committee. N Engl J Med. 1989 Apr 27;320(17):1097-102. doi: 10.1056/NEJM198904273201701.
Results Reference
background
PubMed Identifier
1987459
Citation
O'Hollaren MT, Yunginger JW, Offord KP, Somers MJ, O'Connell EJ, Ballard DJ, Sachs MI. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. N Engl J Med. 1991 Feb 7;324(6):359-63. doi: 10.1056/NEJM199102073240602.
Results Reference
background
PubMed Identifier
1603007
Citation
Bellomo R, Gigliotti P, Treloar A, Holmes P, Suphioglu C, Singh MB, Knox B. Two consecutive thunderstorm associated epidemics of asthma in the city of Melbourne. The possible role of rye grass pollen. Med J Aust. 1992 Jun 15;156(12):834-7. doi: 10.5694/j.1326-5377.1992.tb136994.x.
Results Reference
background
PubMed Identifier
6126624
Citation
Platts-Mills TA, Tovey ER, Mitchell EB, Moszoro H, Nock P, Wilkins SR. Reduction of bronchial hyperreactivity during prolonged allergen avoidance. Lancet. 1982 Sep 25;2(8300):675-8. doi: 10.1016/s0140-6736(82)90709-7.
Results Reference
background
PubMed Identifier
13044326
Citation
HERXHEIMER H. The late bronchial reaction in induced asthma. Int Arch Allergy Appl Immunol. 1952;3(4):323-8. doi: 10.1159/000227979. No abstract available.
Results Reference
background
PubMed Identifier
3115156
Citation
O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis. 1987 Sep;136(3):740-51. doi: 10.1164/ajrccm/136.3.740. No abstract available.
Results Reference
background
PubMed Identifier
10231314
Citation
O'Byrne PM, Wood L. Interleukin-5 and allergic inflammation. Clin Exp Allergy. 1999 May;29(5):573-5. doi: 10.1046/j.1365-2222.1999.00556.x. No abstract available.
Results Reference
background
PubMed Identifier
20228417
Citation
Kloek J, Mortaz E, van Ark I, Lilly CM, Nijkamp FP, Folkerts G. Glutathione prevents the early asthmatic reaction and airway hyperresponsiveness in guinea pigs. J Physiol Pharmacol. 2010 Feb;61(1):67-72.
Results Reference
background
PubMed Identifier
7759431
Citation
Becker AB, Black C, Lilley MK, Bajwa K, Ford-Hutchinson AW, Simons FE, Tagari P. Antiasthmatic effects of a leukotriene biosynthesis inhibitor (MK-0591) in allergic dogs. J Appl Physiol (1985). 1995 Feb;78(2):615-22. doi: 10.1152/jappl.1995.78.2.615.
Results Reference
background
PubMed Identifier
2389910
Citation
Coyle AJ, Page CP, Atkinson L, Flanagan R, Metzger WJ. The requirement for platelets in allergen-induced late asthmatic airway obstruction. Eosinophil infiltration and heightened airway responsiveness in allergic rabbits. Am Rev Respir Dis. 1990 Sep;142(3):587-93. doi: 10.1164/ajrccm/142.3.587.
Results Reference
background
PubMed Identifier
3804916
Citation
Hamel R, McFarlane CS, Ford-Hutchinson AW. Late pulmonary responses induced by Ascaris allergen in conscious squirrel monkeys. J Appl Physiol (1985). 1986 Dec;61(6):2081-7. doi: 10.1152/jappl.1986.61.6.2081.
Results Reference
background
PubMed Identifier
8756799
Citation
Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308-17. doi: 10.1164/ajrccm.154.2.8756799.
Results Reference
background
PubMed Identifier
28665197
Citation
Oliveria JP, Salter BM, MacLean J, Kotwal S, Smith A, Harris JM, Scheerens H, Sehmi R, Gauvreau GM. Increased IgE+ B Cells in Sputum, but Not Blood, Bone Marrow, or Tonsils, after Inhaled Allergen Challenge in Subjects with Asthma. Am J Respir Crit Care Med. 2017 Jul 1;196(1):107-109. doi: 10.1164/rccm.201611-2274LE. No abstract available.
Results Reference
derived
Links:
URL
http://fhs.mcmaster.ca/crlab/
Description
McMaster Cardio Respiratory Laboratory Site
Learn more about this trial
Kinetics of IgE Memory B Cells, Plasmablasts and Plasma Cells After Whole Lung Allergen Challenge in Mild Asthmatics
We'll reach out to this number within 24 hrs